{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:48:27Z","timestamp":1781106507990,"version":"3.54.1"},"reference-count":28,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2021,6,1]]},"DOI":"10.1188\/21.cjon.259-266","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T08:30:38Z","timestamp":1621585838000},"page":"259-266","source":"Crossref","is-referenced-by-count":1,"title":["Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy"],"prefix":"10.1188","volume":"25","author":[{"given":"Catherine","family":"Kobza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Abdel-Rahman, O., & Alorabi, M. (2015). Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: Preclinical and clinical considerations. Expert Review of Anticancer Therapy, 15(7), 829\u2013837. https:\/\/doi.org\/10.1586\/14737140.2015.1047766","DOI":"10.1586\/14737140.2015.1047766"},{"key":"2","unstructured":"American Cancer Society. (2019). Cancer facts and figures 2019. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-..."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Armenian, S.H., Lacchetti, C., Barac, A., Carver, J., Constine, L.S., Denduluri, N., . . . Lenihan, D. (2017). Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 35(8), 893\u2013911. https:\/\/doi.org\/10.1200\/jco.2016.70.5400","DOI":"10.1200\/JCO.2016.70.5400"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bansal, N., Adams, M.J., Ganatra, S., Colan, S.D., Aggarwal, S., Steiner, R., . . . Lipshultz, S.E. (2019). Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology, 5, 18. https:\/\/doi.org\/10.1186\/s40959-019-0054-5","DOI":"10.1186\/s40959-019-0054-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Bernstein, D. (2018). Anthracycline cardiotoxicity. Circulation Research, 122(2), 188\u2013190. https:\/\/doi.org\/10.1161\/circresaha.117.312395","DOI":"10.1161\/CIRCRESAHA.117.312395"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Bui, A.L., Horwich, T.B., & Fonarow, G.C. (2010). Epidemiology and risk profile of heart failure. Nature Reviews Cardiology, 8(1), 30\u201341. https:\/\/doi.org\/10.1038\/nrcardio.2010.165","DOI":"10.1038\/nrcardio.2010.165"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Cadeddu, C., Mercurio, V., Spallarossa, P., Nodari, S., Triggiani, M., Monte, I., . . . Mercuro, G. (2016). Preventing antiblastic drug-related cardiomyopathy: Old and new therapeutic strategies. Journal of Cardiovascular Medicine, 17, e64\u2013e75.","DOI":"10.2459\/JCM.0000000000000382"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C.A., Veglia, F., . . . Cipolla, C.M. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 131(22), 1981\u20131988. https:\/\/doi.org\/10.1161\/circulationaha.114.013777","DOI":"10.1161\/CIRCULATIONAHA.114.013777"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Colombo, A., Cipolla, C., Beggiato, M., & Cardinale, D. (2013). Cardiac toxicity of anticancer agents. Current Cardiology Reports, 15(5). https:\/\/doi.org\/10.1007\/s11886-013-0362-6","DOI":"10.1007\/s11886-013-0362-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Cuomo, A., Rodolico, A., Galdieri, A., Russo, M., Campi, G., Franco, R., . . . Mercurio, V. (2019). Heart failure and cancer: Mechanisms of old and new cardiotoxic drugs in cancer patients. Cardiac Failure Review, 5(2), 112\u2013118. https:\/\/doi.org\/10.15420\/cfr.2018.32.2","DOI":"10.15420\/cfr.2018.32.2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., . . . Jordan, K. (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology, 31(2), 171\u2013190.","DOI":"10.1016\/j.annonc.2019.10.023"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Cuschieri, S. (2019). The STROBE guidelines. Saudi Journal of Anaesthesia, 13(5), 31. https:\/\/doi.org\/10.4103\/sja.sja_543_18","DOI":"10.4103\/sja.SJA_543_18"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Denlinger, C.S., Sanft, T., Baker, K.S., Broderick, G., Demark-Wahnefried, W., Friedman, D.L., . . . Freedman-Cass, D.A. (2018). Survivorship, version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 16(10), 1216\u20131247. https:\/\/doi.org\/10.6004\/jnccn.2018.0078","DOI":"10.6004\/jnccn.2018.0078"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Georgakopoulos, P., Roussou, P., Matsakas, E., Karavidas, A., Anagnostopoulos, N., Marinakis, T., . . . Ahimastos, A. (2010). Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up. American Journal of Hematology, 85(11), 894\u2013896. https:\/\/doi.org\/10.1002\/ajh.21840","DOI":"10.1002\/ajh.21840"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Henriksen, P.A. (2017). Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention. Heart, 104(12), 971\u2013977. https:\/\/doi.org\/10.1136\/heartjnl-2017-312103","DOI":"10.1136\/heartjnl-2017-312103"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Janbabai, G., Nabati, M., Faghihinia, M., Azizi, S., Borhani, S., & Yazdani, J. (2017). Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovascular Toxicology, 17(2), 130\u2013139. https:\/\/doi.org\/10.1007\/s12012-016-9365-z","DOI":"10.1007\/s12012-016-9365-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Kalam, K., & Marwick, T.H. (2013). Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. European Journal of Cancer, 49(13), 2900\u20132909. https:\/\/doi.org\/10.1016\/j.ejca.2013.04.030","DOI":"10.1016\/j.ejca.2013.04.030"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Lefrak, E.A., Pi\u0165ha, J., Rosenheim, S., & Gottlieb, J.A. (1973). A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32(2), 302\u2013314.","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Li, X., Li, Y., Zhang, T., Xiong, X., Liu, N., Pang, B., . . . Xing, Y. (2020). Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials. Pharmacological Research, 151, 104577.","DOI":"10.1016\/j.phrs.2019.104577"},{"key":"20","doi-asserted-by":"crossref","unstructured":"McGowan, J.V., Chung, R., Maulik, A., Piotrowska, I., Walker, J.M., & Yellon, D.M. (2017). Anthracycline chemotherapy and cardiotoxicity. Cardiovascular Drugs and Therapy, 31(1), 63\u201375.","DOI":"10.1007\/s10557-016-6711-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Miller, A.J., & Arnold, A.C. (2018). The renin\u2013angiotensin system in cardiovascular autonomic control: Recent developments and clinical implications. Clinical Autonomic Research, 29(2), 231\u2013243. https:\/\/doi.org\/10.1007\/s10286-018-0572-5","DOI":"10.1007\/s10286-018-0572-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Moher, D. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA statement. Annals of Internal Medicine, 151(4), 264.","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Moher, D., Hopewell, S., Schulz, K.F., Montori, V., Gotzsche, P.C., Devereaux, P.J., . . . Altman, D.G. (2010). CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomized trials. BMJ, 340, c869. https:\/\/doi.org\/10.1136\/bmj.c869","DOI":"10.1136\/bmj.c869"},{"key":"24","unstructured":"Radulescu, D., Buzdugan, E., Ciuleanu, T.E., Todor, N., & Stoicescu, L. (2013). Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors? Journal of the Balkan Union of Oncology, 18(4), 1052\u20131057."},{"key":"25","doi-asserted-by":"crossref","unstructured":"Rock, C.L., Thomson, C., Gansler, T., Gapstur, S.M., McCullough, M.L., Patel, A.V., . . . Doyle, C. (2020). American Cancer Society guideline for diet and physical activity for cancer prevention. CA: A Cancer Journal for Clinicians, 70(4), 245\u2013271.","DOI":"10.3322\/caac.21591"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Swain, S.M., Whaley, F.S., & Ewer, M.S. (2003). Congestive heart failure in patients treated with doxorubicin. Cancer, 97(11), 2869\u20132879. https:\/\/doi.org\/10.1002\/cncr.11407","DOI":"10.1002\/cncr.11407"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Tan, T.C., Neilan, T.G., Francis, S., Plana, J.C., & Scherrer-Crosbie, M. (2015). Anthracycline-induced cardiomyopathy in adults. Comprehensive Physiology, 5(3), 1517\u20131540.","DOI":"10.1002\/cphy.c140059"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Drazner, M.H., . . . Wilkoff, B.L. (2013). 2013 ACCF\/AHA guideline for the management of heart failure. Journal of the American College of Cardiology, 62(16), e147\u2013e239. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.019","DOI":"10.1016\/j.jacc.2013.05.019"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/25\/3\/cardiac-toxicity-using-angiotensin-converting-enzyme-inhibitors-prevent-anthracycline","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:49:40Z","timestamp":1763754580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/25\/3\/cardiac-toxicity-using-angiotensin-converting-enzyme-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1188\/21.cjon.259-266","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}